Glioblastoma is one of the most malignant types of primary brain tumors. It is a rare tumor, with about 3 new cases per 100,000 individuals per year with a poor prognosis.1 Even though surgery, chemotherapy, and radiotherapy have advanced over the last decade, resulting in a gradual improvement in the survival and quality of life of glioblastoma patients, the prognosis remains depressing.2
Glioblastoma is a complex tumor which is very difficult to treat. Surgery is rarely curative as the tumor cells infiltrate the surrounding tissue and the blood-brain barrier places a limitation on medical therapies.
In conjunction with Helmholtz Zentrum München (HZM), ITM is developing a novel n.c.a. 177Lu-TTM* for intra-cavitary immunoradiotherapy (iRIT) in patients suffering from glioblastoma. N.c.a. 177Lu-TTM* consists of two molecular components – firstly, n.c.a. Lutetium-177 (EndolucinBeta®), a synthetic, low-energy beta-emitting isotope of Lutetium, and secondly, a nondisclosed tumor-targeting molecule TTM*, specifically targeting glioblastoma cells.
HZM is currently leading a Phase I study in three German neurosurgical centers. Upon completion of the study, ITM has the option to take n.c.a 177Lu-TTM* into full clinical development.
*TTM = Tumor-Targeting Molecule; nondisclosed
1 Gallego, 2015, Current Oncology 22(4): e273–e281 and
Bahadur et al., 2019, Oncology Reviews 13(2): 417
2 Gallego, 2015, Current Oncology 22(4): e273–e281 and
Weller et al., 2013, Neuro-Oncology 15(1): 4–27